AF
RXRX icon

Apexium Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Apexium Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$81.6K Buy
16,727
+1,000
+6% +$5.25K ﹤0.01% 287
2025
Q2 		$79.6K Buy
+15,727
New +$77.3K ﹤0.01% 275

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apexium Financial's RXRX Position: Q3 2025 in Review

Apexium Financial increased its Recursion Pharmaceuticals (RXRX) stake by 6.4% in Q3 2025, buying an estimated $5.25K and bringing the position to 16,727 shares worth $81.6K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Apexium Financial first reported a position in RXRX in Q2 2025 and has held it in 2 quarters since. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Apexium Financial held 16,727 shares of Recursion Pharmaceuticals worth $81.6K as of Q3 2025.
  • Apexium Financial bought 1,000 Recursion Pharmaceuticals shares in Q3 2025, an estimated $5.25K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Apexium Financial's portfolio in Q3 2025, its #287 holding.
  • Apexium Financial first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Apexium Financial's 13F filing for Q3 2025, filed 18 Nov 2025.